drugset
Drugs / MND-ADA
last change Oct 2021 re-read 3 minutes ago

MND-ADA

also known as MND (myeloproliferative sarcoma virus, negative control region deleted, dl587rev primer binding site)-ADA
Developed for
severe combined immunodeficiency
Investigated by
Donald B. Kohn, M.D. · FDA Office of Orphan Products Development · National Institutes of Health (NIH)

Trials 1

today NCT00794508 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00794508 Nov 2008 → Dec 2014 severe combined immunodeficiency Donald B. Kohn, M.D. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MND-ADA “Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.” NCT00794508 ↗
Known as MND (myeloproliferative sarcoma virus, negative control region deleted, dl587rev primer binding site)-ADA “Autologous bone marrow CD34+ cells were transduced ex vivo with the MND (myeloproliferative sarcoma virus, negative control region deleted, dl587rev primer binding site)-ADA...” PMID 33974038 ↗ Oct 2021
Action Restore “adding a normal copy of the human ADA gene into stem cells” NCT00794508 ↗
Route Intravenous “given back by IV” NCT00794508 ↗